Pediatrix Medical Group (MD) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on November 1, 2024, might help the stock move higher if these key numbers are ...

Pediatric service provider Pediatrix Medical Group, Inc. (MD) continues its recovery on the back of improving operating results and rising commercial birth share in Florida. The company has seen its shares rise 45.8% in the past three months, recovering from the declines witnessed around the middle of this year, outpacing the industry's 3.7% growth. The company also outperformed the S&P 500's return of 2.4% during the past three months. Given the impressive performance so far, can investors still consider b ...

After reaching an important support level, Pediatrix Medical Group, Inc. (MD) could be a good stock pick from a technical perspective. MD recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-t ...

A month has gone by since the last earnings report for Pediatrix Medical Group (MD) . Shares have added about 9.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Pediatrix Medical Group due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Pediatrix Q2 Earnings Beat E ...

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time. Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, inves ...

Pediatrix Medical Group (MD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices - - has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changi ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time. Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead ...

Shares of Pediatrix Medical Group, Inc. (MD) gained 7.4% since it reported second-quarter 2024 results on Aug 6. Positive investor sentiment might have been caused due to stable patient volumes and improved hospital contract administrative fees. However, the upside was partly offset by an increased expense level resulting from rising practice salaries and benefits, and transformational and restructuring-related costs. MD reported second-quarter 2024 adjusted earnings per share (EPS) of 34 cents, which outpa ...

Financial Data and Key Metrics Changes - The second quarter operating results exceeded expectations, driven by same unit revenue growth and operating efficiencies [4] - Adjusted EBITDA for the full year 2024 is maintained at between $200 million and $220 million [6][10] - Operating cash flow generated in the second quarter was $109 million, compared to $93 million in the prior year [13] - Net debt position declined to roughly $600 million, maintaining leverage at or below 3x based on adjusted EBITDA outlook [14] Business Line Data and Key Metrics Changes - NICU days declined slightly, while hospital-based volume growth was driven by subspecialties such as newborn nursery and pediatric intensive care [4] - Maternal fetal medicine volume growth was strong, but pediatric urgent care experienced volume declines [5] - The company plans to exit almost all office-based practices except maternal fetal medicine during 2024, which is expected to generate approximately $30 million in annualized adjusted EBITDA [6][8] Market Data and Key Metrics Changes - The revenue profile post-restructuring will consist of approximately 80% hospital-based services and 20% office space [9] - The payer mix improved, with a greater mix of non-governmental payers versus Medicaid, although the $3 million settlement did not significantly impact this improvement [18] Company Strategy and Development Direction - The company is undergoing a broad-based portfolio restructuring plan aimed at focusing on service lines with solid financial underpinnings [6][10] - The restructuring includes exiting a significant number of office-based practices, which is expected to enhance operational efficiencies and margin profiles [6][8] - The company remains committed to investments in clinical research and education, foundational to its mission [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operating plans in motion, which are expected to enable the company to continue its mission effectively [12] - The company anticipates that the full impact of restructuring activities will be realized in 2025, with consistent performance expected in the third and fourth quarters of 2024 [22][27] - Management views the payer contracting landscape as stable, with normal course renewals continuing [19] Other Important Information - Kasandra Rossi has been appointed as Executive Vice President, Chief Financial Officer, and Treasurer effective October 1 [11] - The company recorded long-lived asset impairments and losses on disposals related to the portfolio restructuring, all of which were non-cash expenses [13] Q&A Session Summary Question: Restructuring costs increase - Management confirmed that restructuring costs have increased to about $40 million due to the addition of more practices to be exited [16] Question: Impact of office-based practice exits - The bulk of office exits are slated for the third and fourth quarters, with the full impact expected in 2025 [22] Question: Pricing growth momentum - Management indicated that payer mix played a slightly greater role in overall same unit pricing compared to contract and admin fees [30] Question: Growth perspective post-restructuring - The company is focused on stabilizing margins and moving towards growth, particularly in 2025, with unique opportunities in the 80:20 mix of services [34] Question: Discussions with managed Medicaid - Medicaid managed care represents a significant portion of the governmental mix, largely classified as pass-through from state Medicaid schedules [37]

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.68%. A quarter ago, it was expected that this physician group would post earnings of $0.18 per share when it actually produced earnings of $0.20, delivering a surprise of 11.11%. Over the last four quarter ...